Stability Evaluation and Pharmacokinetic Profiling of Vepdegestrant in Rodents Using Liquid Chromatography–Tandem Mass Spectrometry
Molecules · 27.08.2024 · 29 (17) · 4048
DOI: 10.3390/molecules29174048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 27.08.2024. Verfasst von Hae-In Choi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Republic of Korea. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, PRIDE research institute funding program at Chungnam National University.
Abstract (Originalsprache)
Vepdegestrant (formerly ARV-471), a novel proteolysis-targeting chimera (PROTAC), targets estrogen receptor alpha (ERα) for degradation, offering a promising option to treat advanced ER-positive breast cancer. We developed and validated a sensitive and rapid liquid chromatography–tandem mass spectrometry method to quantify vepdegestrant in rodent plasma using bavdegalutamide (formerly ARV-110) as an internal standard. Plasma samples were prepared with protein precipitation using acetonitrile and analyzed using reverse-phase C18 columns and a mobile phase of 10 mM ammonium formate in distilled water and acetonitrile. The method demonstrated linearity from 1 to 1000 ng/mL in mouse and rat plasma, meeting all validation criteria, and successfully applied to in vivo and in vitro studies. Pharmacokinetic analysis revealed low-to-moderate clearance (313.3, 1053 mL/h/kg) and oral bioavailability (17.91, 24.12%) of vepdegestrant in mice and rats, respectively. It was unstable in buffer solutions across pH 2–10 and in phosphate-buffered saline (pH 7.4), likely due to adsorption, but remained stable in mouse and rat plasma at varying temperatures. In liver microsomes, vepdegestrant exhibited moderate stability in rats but was stable in mice, dogs, and humans. These findings enhance the understanding of pharmacokinetic properties of vepdegestrant supporting further development of PROTAC drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Republic of Korea.
- College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, Gimhae 50834, Republic of Korea.
ORCID-Profile: Hae-In Choi, Jin Woo Kim, Tae-Sung Koo
Förderung
- National Research Foundation of Korea
- PRIDE research institute funding program at Chungnam National University
Zitieren
APA
Choi, H. I., Choi, J., Kim, J. W., Lee, Y. H., Cho, K. H., & Koo, T. S. (2024). Stability Evaluation and Pharmacokinetic Profiling of Vepdegestrant in Rodents Using Liquid Chromatography–Tandem Mass Spectrometry. Molecules, 29(17), 4048. https://doi.org/10.3390/molecules29174048
Vancouver
Choi HI, Choi J, Kim JW, Lee YH, Cho KH, Koo TS. Stability Evaluation and Pharmacokinetic Profiling of Vepdegestrant in Rodents Using Liquid Chromatography–Tandem Mass Spectrometry. Molecules. 2024;29(17):4048. doi:10.3390/molecules29174048
BibTeX
@article{Choi2024,
author = {Choi, Hae-In and Choi, Jinyoung and Kim, Jin Woo and Lee, Yoon Ha and Cho, Kwan Hyung and Koo, Tae-Sung},
title = {Stability Evaluation and Pharmacokinetic Profiling of Vepdegestrant in Rodents Using Liquid Chromatography–Tandem Mass Spectrometry},
journal = {Molecules},
year = {2024},
volume = {29},
number = {17},
pages = {4048},
doi = {10.3390/molecules29174048}
}
EUVIMED